Immune Checkpoint Inhibitor-Chemo Combo Boosts OS in Advanced Endometrial Cancer

Source link :

SAN DIEGO — The addition of an immune checkpoint inhibitor (ICI) to chemotherapy up front improved overall survival (OS) in patients with advanced or recurrent endometrial cancer, regardless of mismatch repair (MMR) status, according to two trials. In the phase III RUBY Part 1, patients treated with dostarlimab (Jemperli) and chemotherapy had a median OS […]

Author : News Health

Publish date : 2024-03-17 19:18:02

Copyright for syndicated content belongs to the linked Source.